Nanodiamonds-mediated doxorubicin nuclear delivery to inhibit lung metastasis of breast cancer

Biomaterials

Volumn 34, Issue 37, 2013, Pages 9648-9656

  Xiao, Jisheng ^a   Duan, Xiaopin ^a,b   Yin, Qi ^a   Zhang, Zhiwen ^a   Yu, Haijun ^a   Li, Yaping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Doxorubicin; Drug delivery; Metastasis; Nanodiamonds

Indexed keywords

BREAST CANCER; BREAST CANCER TREATMENT; DOXORUBICIN; DRUG DELIVERY SYSTEM; HIGH DRUG LOADINGS; METASTASIS; PHYSICAL ADSORPTION; SYSTEMIC TOXICITIES;

BIOLOGICAL ORGANS; CELL DEATH; DISEASES; DRUG DELIVERY; PATHOLOGY;

NANODIAMONDS;

DOXORUBICIN; MACROGOL 2000; NANOCOATING; NANODIAMOND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AQUEOUS SOLUTION; ARTICLE; BREAST CANCER; CELL NUCLEUS; CELLULAR DISTRIBUTION; CIRCULATION TIME; CONTROLLED STUDY; DISPERSION; DRUG ACCUMULATION; DRUG ADSORPTION; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; HISTOCOMPATIBILITY; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

BREAST CANCER; DOXORUBICIN; DRUG DELIVERY; METASTASIS; NANODIAMONDS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NANODIAMONDS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84884815388     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.08.056     Document Type: Article

References (39)

1. Christofori G. New signals from the invasive front. Nature 2006, 441:444-450.
2. Parker B., Sukumar S. Distant metastasis in breast cancer: molecular mechanisms and therapeutic targets. Cancer Biol Ther 2003, 2:14-21.
3. Schroeder A., Heller D.A., Winslow M.M., Dahlman J.E., Pratt G.W., Langer R., et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2012, 12:39-50.
4. Xiao J., Duan X., Yin Q., Miao Z., Yu H., Chen C., et al. The inhibition of metastasis and growth of breast cancer by blocking the NF-κB signaling pathway using bioreducible PEI-based/p65 shRNA complex nanoparticles. Biomaterials 2013, 34:5381-5390.
5. Danhier F., Feron O., Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. JControl Release 2010, 148:135-146.
6. Mackey J.R., Kerbel R.S., Gelmon K.A., McLeod D.M., Chia S.K., Rayson D., et al. Controlling angiogenesis in breast cancer: a systematic review of antiangiogenic trials. Cancer Treat Rev 2012, 38:673-688.
7. Lam R., Ho D. Nanodiamonds as vehicles for systemic and localized drug delivery. Expert Opin Drug Deliv 2009, 6:883-895.
8. Kaur R., Badea I. Nanodiamonds as novel nanomaterials for biomedical applications: drug delivery and imaging systems. Int J Nanomed 2013, 8:203-220.
9. Zhu Y., Li J., Li W., Zhang Y., Yang X., Chen N., et al. The biocompatibility of nanodiamonds and their application in drug delivery systems. Theranostics 2012, 2:302-312.
10. Krueger A., Lang D. Functionality is key: recent progress in the surface modification of nanodiamond. Adv Funct Mater 2012, 22:890-906.
11. Petráková V., Taylor A., Kratochvílová I., Fendrych F., Vacík J., Kučka J., et al. Luminescence of nanodiamond driven by atomic functionalization: towards novel detection principles. Adv Funct Mater 2012, 22:812-819.
12. MeinhardtT Lang D., Dill H., Krueger A. Pushing the functionality of diamond nanoparticles to new horizons: orthogonally functionalized nanodiamond using click chemistry. Adv Funct Mater 2011, 21:494-500.
13. Liu K.K., Zheng W.W., Wang C.C., Chiu Y.C., Cheng C.L., Lo Y.S., et al. Covalent linkage of nanodiamond-paclitaxel for drug delivery and cancer therapy. Nanotechnology 2010, 21:315106-315119.
14. Chen M., Pierstorff E.D., Lam R., Li S.Y., Huang H., Osawa E., et al. Nanodiamond-mediated delivery of water-insoluble therapeutics. ACS Nano 2009, 3:2016-2022.
15. Li J., Zhu Y., Li W., Zhang X., Peng Y., Huang Q. Nanodiamonds as intracellular transporters of chemotherapeutic drug. Biomaterials 2010, 31:8410-8418.
16. Shimkunas R.A., Robinson E., Lam R., Lu S., Xu X., Zhang X.Q., et al. Nanodiamond-insulin complexes as pH-dependent protein delivery vehicles. Biomaterials 2009, 30:5720-5728.
17. Chen M., Zhang X.Q., Man H.B., Lam R., Chow E.K., Ho D. Nanodiamond vectors functionalized with polyethylenimine for siRNA delivery. JPhys ChemLett 2010, 1:3167-3171.
18. Zhang X.Q., Chen M., Lam R., Xu X., Osawa E., Ho D. Polymer-functionalized nanodiamond platforms as vehicles for gene delivery. ACS Nano 2009, 3:2609-2616.
19. Alhaddad A., Adam M.P., Botsoa J., Dantelle G., Perruchas S., Gacoin T., et al. Nanodiamond as a vector for siRNA delivery to ewing sarcoma cells. Small 2011, 7:3087-3095.
20. Chow E.K., Zhang X.Q., Chen M., Lam R., Robinson E., Huang H.J., et al. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci Transl Med 2011, 3:73ra21.
21. Li X.X., Shao J.Q., Qin Y., Shao C., Zheng T.T., Ye L. TAT-conjugated nanodiamond for the enhanced delivery of doxorubicin. JMater Chem 2011, 21:7966-7973.
22. Williams O.A., Hees J., Dieker C., Jäger W., Kirste L., Nebel C.E. Size-dependent reactivity of diamond nanoparticles. ACS Nano 2010, 4:4824-4830.
23. Schrand A.M., Ciftan Hens S.A., Shenderova O.A. Nanodiamond particles: properties and perspectives for bioapplications. Crit Rev Solid State Mat Sci 2009, 34:18-74.
24. Neugart F., Zappe A., Jelezko F., Tietz C., Boudou J.P., Krueger A., et al. Dynamics of diamond nanoparticles in solution and cells. Nano Lett 2007, 7:2588-3591.
25. Duan X., Li Y. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small 2013, 9:1521-1532.
26. Xiao K., Li Y., Luo J., Lee J.S., Xiao W., Gonik A.M., et al. The effect of surface charge on invivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 2011, 32:3435-3446.
27. Xiao J., Duan X., Yin Q., Chen L., Zhang Z., Li Y. Low molecular weight polyethylenimine-graft-tween 85 for effective gene delivery: synthesis and invitro characteristics. Bioconjugate Chem 2012, 23:222-231.
28. Tacar O., Sriamornsak P., Dass C.R. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. JPharm Pharmacol 2013, 65:157-170.
29. Reinhardt H.C., Hasskamp P., Schmedding I., Morandell S., van Vugt M.A.T.M., Wang X., et al. DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Mol Cell 2010, 40:34-49.
30. Huang H., Pierstorff E., Osawa E., Ho D. Active nanodiamond hydrogels for chemotherapeutic delivery. Nano Lett 2007, 7:3305-3314.
31. Kang B., Li J., Chang S., Dai M., Ren C., Dai Y., et al. Subcellular tracking of drug release from carbon nanotube vehicles in living cells. Small 2012, 8:777-782.
32. Lipka J., Semmler-Behnke M., Sperling R.A., Wenk A., Takenaka S., Schleh C., et al. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 2010, 31:6574-6581.
33. Piegari E., De Angelis A., Cappetta D., Russo R., Esposito G., Costantino S., et al. Doxorubicin induces senescence and impairs function of human cardiac progenitor cells. Basic Res Cardiol 2013, 108:334-352.
34. Ma J., Wang Y., Zheng D., Wei M., Xu H., Peng T. Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways. Cardiovasc Res 2013, 97:77-87.
35. Lankveld, Rayavarapu R.G., Krystek P., Oomen A.G., Verharen H.W., van Leeuwen T.G., et al. Blood clearance and tissue distribution of PEGylated and non-PEGylated gold nanorods after intravenous administration in rats. Nanomedicine 2011, 6:339-349.
36. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011, 63:131-135.
37. Yamada Y., Harashima H. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv Drug Deliv Rev 2008, 60:1439-1462.
38. Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2012, 64:24-36.
39. Wang Z., Yu Y., Dai W., Cui J., Wu H., Yuan L., et al. Aspecific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth. Biomaterials 2013, 34:756-764.